Genetic Disorders in the Growth Hormone – Insulin-Like Growth Factor-I AxisWalenkamp M.J.E. · Wit J.M.
Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands Corresponding Author
Department of Pediatrics J6-S, Leiden University Medical Center
PO Box 9600
NL–2300 RC Leiden (The Netherlands)
Tel. +31 71 526 2824, Fax +31 71 524 8198, E-Mail email@example.com
In the last few years, our knowledge of genetically determined causes of short stature has greatly increased by reports of challenging patients, who offered the opportunity to study genes that play a role in growth. Since the first paper that showed the etiology of Laron syndrome [Godowski PJ, et al: Proc Natl Acad Sci USA 1989;86:8083–8087], many mutations in the growth hormone (GH) receptor have been identified. Recently, new mutations or deletions have been found in several components of the GH–insulin-like growth factor-I (IGF-I) axis: a homozygous mutation of the GH1 gene, resulting in a bio-inactive GH; mutations in the STAT5b gene, which plays a major role in the GH signal transduction; a homozygous missense mutation in the IGF-I gene; heterozygous mutations in the IGF-I receptor gene and a homozygous deletion of the acid-labile subunit gene. In this mini review, we describe the clinical and biochemical features of these genetic defects. Genetic analysis has become essential in the diagnostic workup of a patient with short stature. However, regarding the time consuming nature of molecular analysis, it is important to carefully select the patient for specific genetic evaluation. To help in this selection process, we developed flowcharts, based on the recently described patients, that can be used as guidelines in the diagnostic process of patients with severe short stature of unknown origin.
© 2006 S. Karger AG, Basel
Body growth is regulated by many genes, of which only a few have been clarified. However, in the last years our knowledge of genetically determined causes of short stature has greatly increased and genetic analysis is becoming essential in the diagnosis of short stature.
A review article in this journal in 2003 described the most important genetically determined causes of short stature and the genes involved . Only 2 years later important papers were published presenting new diseases, caused by genetic defects in the growth hormone (GH)–insulin-like growth factor-I (IGF-I) axis. In this review, we will give an overview of the clinical aspects and the biochemical parameters for these genetic defects in the GH–IGF-I axis and we present a flow chart for the diagnostic approach of these disorders.
We will focus on those children, whose height is more than 2.5 SDS below the mean of the population reference. The first discriminating step in the diagnostic process of short stature is the presence or absence of dysmorphic features or disproportionate stature. Hereditary causes of short stature in combination with dysmorphic or disproportionate features were reviewed by Kant et al. . In summary, in case of dysmorphic features a chromosomal abnormality (numeric, structural, mosaic or uniparental disomy) is suspected and karyotyping is indicated. Dysmorphic features may be minor, as seen in patients with Silver-Russell syndrome, who have in 10% of the cases uniparental disomy of chromosome 7. One can consider to look for Noonan syndrome, Prader Willi syndrome of 22q11 deletion in patients with short stature and subtle dysmorphic features.
Disproportionate short stature is the result of skeletal dysplasia, a category of disorders affecting in most cases the epiphysis, metaphysis or diaphysis of the long bones, with specific radiological characteristics. The genetic basis of these disorders is emerging, as many skeletal dysplasia gene loci have been identified. More than half of all patients with skeletal dysplasias have a mutation at COL2A1 or FGFR3. Mutations in the SHOX gene are even more frequent, but do not always present with skeletal abnormalities. 2–3% of the children with idiopathic short stature have a SHOX deletion or mutation . It is particularly worthwhile to look for a SHOX deletion or mutation because treating these children with GH results in a similar catch-up growth as seen in girls with Turner syndrome treated with GH. Recently, deletions in the pseudoautosomal region downstream the SHOX gene were identified in patients with Leri Weill dyschondrosteosis . Phenotypically these patients were indistinguishable from patients with SHOX deletion.
The child with proportionate short stature should be screened for organic, systemic and endocrine disorders. In children born small for gestation age (SGA) and a small head circumference chromosome disorders, congenital infections or exposure to toxins should be considered. After excluding organic and systemic diseases IGF-I and IGFBP-3 measurements serve to focus on disturbances in the GH–IGF-I axis. As further diagnostic procedures heavily depend on IGF-I and IGFBP-3 concentrations, we would like to stress the importance of a reliable IGF-I and IGFBP-3 assay.
The GH–IGF-I axis plays a key role in regulating somatic growth. Genetic defects in one of the components (pituitary GH secretion, GH receptor (GHR), post-receptor signaling and IGF-I) of this axis usually result in proportionate growth retardation.In the last years, several patients with new genetic defects in the GH–IGF-I axis have been identified. We will summarize the genetic, biochemical and clinical aspects of these new findings (table 1).
Classical GH deficiency can be the result of a mutation in the GH releasing hormone receptor (GHRH-R) gene , a genetic defect in one of the genes playing a role in the ontogenesis of the GH producing cells in the anterior pituitary (POU1F1, PROP1, HESX1, LHX3, LHX4, etc.)  or a mutation or deletion of the GH1 gene . Dysfunctional GH variants, caused by heterozygous missense mutations in the GH1 gene, have been described by Takahashi et al. . Recently, the first homozygous missense mutation in the GH1 gene (GH-C53S) has been described . This mutation leads to the absence of the disulfide bridge Cys-53 to Cys-165, resulting in reduced GHR binding and signaling. These genetic defects are comparatively rare causes of short stature.
Recent studies demonstrate high diversity in the proximal promoter region of the GH1 gene, resulting in some haplotypes that are associated with a reduced level of gene expression, while other haplotypes were associated with increased expression . One can speculate that a haplotype, associated with reduced expression of GH, results in a condition with low spontaneous GH secretion and thus low levels of IGF-I, while stimulated GH secretion may be normal.
The biological effects of GH can only be reached in the presence of a normal functioning GHR, and an intact post-receptor signaling pathway. Deletions and mutations in the extracellular domain of the GHR gene result in classical GH insensitivity (Laron syndrome). More recently, mutations in the transmembrane and intracellular domain of the receptor were identified, resulting in GH insensitivity syndrome with normal or high levels of GH binding protein [10,11,12].
The first report of a specific molecular defect in the GH signal transduction was published by Kofoed et al. . The authors described a patient with a homozygous missense mutation in the highly conserved SH2 domain of the STAT5b gene, which is essential for the GH signaling cascade and IGF-I transcription. At the moment of writing this review, several patients with homozygous mutations in the STAT5b gene have been described: a frame shift mutation [14, 15], a nonsense mutation , another frameshift mutation , and a splice site mutation . All patients appear to show hyperprolactinemia; some of them have a serious immunodeficiency, while others show no such clinical symptoms.
Recently, a heterozygous mutation of the IĸB gene was described [19, 20]. IĸB is part of the NFĸB signaling pathway, playing a major role in immune responses. Besides severe immune deficiency, this patient also had signs of partial GH insensitivity, suggesting that the NFĸB pathway could play a role in the GH signal transduction.
One of the biological effects of GH is stimulating IGF-I production, which is mainly taking place in the liver, but also in all other cells of the body. IGF-I has endocrine, paracrine and autocrine functions. IGF-I secretion is under control of many other factors than GH (e.g. nutrition). IGF-I, IGF-II and insulin are the most important regulators of prenatal growth. Postnatally, IGF-I remains important, while the role of IGF-II is still unclear. In 1996, one patient with a homozygous deletion of exons 4 and 5 of the IGF-I gene was described. Phenotypically he showed intrauterine growth retardation, postnatal growth failure, microcephaly, mental retardation, sensorineural deafness and multiple dysmorphic features . In 2003, a patient with intrauterine growth retardation, short stature, delayed psychomotor development and sensorineural deafness was described, with a homozygous mutation, changing the normal amino acid sequence of the E domain of the IGF-I precursor, resulting in low circulating levels of IGF-I . In 2005, we described the first patient with a homozygous missense mutation of the IGF-I gene . The phenotype of this 55-year-old patient was similar to that of the patient with an IGF-I deletion . Family members with a heterozygous IGF-I mutation were shorter and had lower head circumferences than family members without the mutation. Recently, a boy was presented with a partial IGF-I deficiency due to a homozygous missense mutation of the IGF-I gene, resulting in pre- and postnatal growth retardation, microcephaly, mild developmental delay and normal hearing tests .
In the circulation IGF-I is bound to binding proteins (IGF-binding proteins, IGFBP’s). These proteins exhibit specific characteristics in relation to delivery of IGF-I to different tissues. IGFBP-3 production is strongly dependent on GH. IGFBP-3 forms with IGF-I and acid-labile subunit (ALS) a ternary complex in the circulation. A homozygous deletion of the ALS gene, resulting in a ‘circulating IGF-I deficiency’, was described in 2004 . This patient was not very short, but had a very delayed puberty. Later, a boy with a similar phenotype was reported .
IGF-I receptors (IGF1R) are widely spread through the body. Children with a deletion of the distal long-arm of chromosome 15, which includes the IGF1R gene, are short . It was assumed that specific mutations/deletions of the IGF1R gene could result in growth retardation.
The first report on mutations in the IGF1R gene was published in 2003 by Abuzzahab et al. : a compound heterozygous mutation of the IGF1R gene, resulting in reduced IGF-I binding and decreased receptor phosphorylation and a nonsense mutation in exon 2, resulting in reduced expression of IGF1R. Recently, a heterozygous mutation in the cleavage site of the proreceptor of IGF1R was reported in a 6-year-old Japanese girl and her mother . We described a mother and daughter with a heterozygous missense mutation in the intracellular part of the IGF1R . A 13.6-year-old girl was presented with a heterozygous missense mutation in the highly conserved N-terminal fibronectin type III domain of the IGF1R . Recently, a new heterozygous missense mutation at the α subunit of the IGF-I receptor was described in a 4-year-old girl with short stature (–3.6 SDS) and her mother .
Although we acknowledge that undoubtedly future studies will show additional cases of the genetic defects described above, as well as new genetic disorders, we think that developing a diagnostic algorithm might be helpful in the evaluation of severely short children. For this purpose, we developed some flowcharts, based on the recently described patients, in combination with theoretical considerations. The flowcharts can be used as guidelines in the diagnostic process of patients with idiopathic short stature. As our knowledge of genetic causes of short stature is increasing rapidly, these diagrams undoubtedly will be subject of adaptation in the coming years.
As main inclusion criterium for considering genetic evaluation, we choose a height SDS of <–2.5, assuming that more pathology is found with a lower height SDS. We believe that deviation of growth is not a valuable parameter, as in some of the earlier described cases growth is far below, but parallel to, the –2.5 SDS line. Similarly, target height cannot be used as criterium, because in some cases parents are short due to the same genetic defect (as in the cases of heterozygous IGF1R mutations).
Figure 1 shows the first diagnostic step in a child with a height <–2.5 SDS. Proportions should be measured and in case of disproportionate short stature a skeletal survey is performed and the child is referred to a clinical geneticist. Radiological abnormalities can point to a known skeletal dysplasia, requiring specific molecular analysis. If no or minimal radiological abnormalities are found, the SHOX and FGFR3 gene can be analyzed, as in some cases mild disproportionate short stature is the only clinical feature [33, 34].
Karyotyping should be carried out when dysmorphic features are found, but also in the absence of dysmorphic features karyotyping is usually carried out in all girls with unexplained short stature. Recently, it was argued that also in boys with short stature karyotyping should be considered, in order to diagnose a XY/X chromosomal pattern . In the dysmorphic child with a normal karyogram a genetic defect of the GH–IGF-I axis is still possible: e.g. the patient with a deletion of the IGF-I gene  and the patients with IGF1R gene mutation showed dysmorphic features . Obviously, if another cause for short stature is found by basic diagnostic screening, genetic analysis of the GH–IGF-I axis is not indicated.
The next criterium in a child with proportionate short stature is the presence or absence of being SGA, defined as a birth weight or length of <–2 SDS. In case of SGA, further investigations will be focused on genetic defects of IGF-I production or sensitivity. Indeed, children with classical GH deficiency or insensitivity are usually not born SGA. In case of SGA, one should look for mutations or deletions in the IGF-I or IGF1R gene or a IGF-I signal transduction defect. In children with a normal birth weight and length additional testing should be focused on disturbances in GH secretion, GH sensitivity or GH signaling.
In children with short stature, born SGA, measuring the head circumference is essential. IGF-I plays a key role in intrauterine growth and cerebral development and prenatally IGF-I secretion is GH independent. Therefore, in SGA children with a small head circumference primary IGF-I deficiency or insensitivity should be considered (fig. 2). The IGF-I level will determine the differential diagnosis. Undetectable IGF-I levels will indicate a homozygous IGF-I deletion or nonsense mutation with absolutely no production of IGF-I. Theoretically, one can expect very low IGF-I levels in cases of a homozygous missense mutation in the IGF-I gene resulting in an abnormal IGF-I protein that can only be partially detected by the assay. IGF-I levels between –2 and 0 SDS could be the result of heterozygous mutations or deletions of IGF-I. It is conceivable that in the future polymorphisms in the promoter region of the IGF-I gene will be found that may explain the short stature in some of these cases. In case of a heterozygous mutation of IGF1R plasma IGF-I is usually elevated, but it can be low if the child is malnourished by extremely poor appetite . In spite of these theoretical possibilities, at present, we do not advise further genetic analysis, at least with the current tools available, in patients with IGF-I levels in the lower normal range. The differential diagnosis in patients with normal or high IGF-I levels consists of a homozygous IGF-I missense mutation, resulting in an abnormal IGF-I molecule, or a heterozygous IGF1R mutation with decreased or absent binding of IGF-I to the mutated receptor. In all these conditions, IGFBP-3 levels are within the normal range.
With a normal head circumference these genetic defects are less probable, but they cannot be completely ruled out. Heterozygous mutations or deletions of the IGF-I or IGF1R gene could present with short stature, SGA and a head circumference >–2 SDS. One may consider to perform in vitro experiments with fibroblasts of patients, that meet these criteria. Depending on the sensitivity of the fibroblasts to IGF-I, the IGF-I gene or the IGF1R gene can be sequenced.
We will now discuss the group of patients with short stature and a normal birth weight and length. The first diagnostic step in these patients is to determine the IGF-I and IGFBP-3 levels. If the IGF-I level is below the normal range (<–2 SDS) the interpretation of the GH peak in a stimulation test determines the next step (fig. 3). An MRI of the pituitary-hypothalamus region should be performed to demonstrate or exclude anatomical defects.
GH deficiency is usually diagnosed if the GH peak is below 20 mU/l (equivalent to 6.6, 7.7 or 10 µg/l, depending on the standard used) in two tests. Depending on the presence of other pituitary hormone deficiencies analysis of transcription factors as HESX-1, PROP-1, and Pit 1 is required. In special cases analysis of LHX3 or LHX4 can be considered. In case of isolated GH deficiency, we advise to analyze the GH and GHRH-R gene, but one can argue that these tests could be restricted to those children in whom a positive family history for short stature or extremely short stature is found.
A GH peak within the lower normal range (20– 30 mU/l) can be the result of a disturbance in the GH secretion and one can consider to analyze the GH promoter gene. In several countries, including the Netherlands, the combination of very low IGF-I and borderline GH peaks after stimulation, is sufficient indication for GH therapy. A low 12- or 24-hour profile, which has been termed ‘neurosecretory dysfunction’ by several investigators, could be used as criterium for analysis of the GH promoter gene.
A normal GH peak (30–40 mU/l) in combination with low IGF-I levels in patients with clinical features of GH deficiency and retarded skeletal maturation can be present. In these cases a low 12- or 24-hour GH profile could reflect a relatively inactive GH promoter haplotype. One should note, however, that in some cases with a GH signaling disorder very low IGF-I levels in the presence of normal GH peaks have been found.
The differential diagnosis of a low IGF-I in combination with a high stimulated GH secretion (GH peak >60 mU/l) consists of: bio-inactive GH, a GHR defect, a GH signal transduction defect (STAT5b mutation) or an ALS deficiency (fig. 4). The response of IGF-I to increasing doses of GH (the IGF-I generation test, described in table 2) will roughly distinguish the conditions characterized by an abnormal GH molecule from GH insensitivity states. We are aware that many different protocols for the IGF-I generation test have been described, and that the diagnostic value of all of them is still uncertain. Theoretically, in patients with a bio-inactive GH, IGF-I will reach normal levels with the lowest GH dose, while in patients with a GHR or post-receptor problem IGF-I will not increase or only on the highest GH dose.
Theoretically, an inactive GH promoter or partial GH insensitivity can result in low IGF-I levels with a normal GH peak in the stimulation test (40–60 mU/l). At his moment, however, we do not propose genetic analysis in these patients, as we think the time and money investment will not be balanced by the results.
In patients with short stature a systematic diagnostic approach may reveal the cause of the growth disorder. The medical history, including birth weight, length and head circumference, and physical examination, including body proportions, are necessary for the first differential diagnosis. Biochemical evaluation will point to a more specific diagnosis, which can be confirmed with molecular techniques. In this review, we discussed new genetic defects in the GH–IGF-I axis and proposed a practical flow chart for the diagnostic work-up.
The proposed diagnostic pathways will lead to maximum results when pediatric endocrinologists, adult endocrinologists, clinical geneticists and molecular biologists cooperate. An unusual presentation of a patient with a growth disorder should alert the clinician to look for new abnormalities in the GH–IGF-I axis or other genes involved in growth.
The other members of the Leiden Growth Genetics Working Group are: S.G. Kanta, A.M. Pereirab, M. Karperienb, c, W. Oostdijkc, H.A. van Duyvenvoordeb, c, M. Losekoota, M.H. Breuninga, J.A. RomijnbaCenter for Human and Clinical Genetics, bDepartment of Endocrinology and Metabolism, and cDepartment of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
Department of Pediatrics J6-S, Leiden University Medical Center
PO Box 9600
NL–2300 RC Leiden (The Netherlands)
Tel. +31 71 526 2824, Fax +31 71 524 8198, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.